The high burden of symptoms associated with cognitive impairment in lung cancer patients: A latent class analysis

Luo, Jie; Liu, Ruiqi; Luo, Yi; Fang, Qinghong; Liu, Suting; Yang, Zhihui; Miao, Jing-xia; Zhang, Lili

doi:10.1016/j.apjon.2023.100200

Cited by 13 publications

(12 citation statements)

References 48 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our study ndings in lung cancer are different from a previous study in lung cancer survivors [22]. In a study of 378 lung cancer survivors based on pain, fatigue, sleep disturbance, depression, and cognitive impairment, all low and all highsymptom groups were identi ed [22].…”

Section: Discussioncontrasting

confidence: 99%

Comparing Symptom Clusters in Cancer Survivors by Cancer Diagnosis: A Latent Class Profile Analysis

Lee,

Han,

Saligan

et al. 2023

Preprint

View full text Add to dashboard Cite

Purpose: Research on symptom clusters in oncology is progressing, but knowledge gaps remain. One question is whether the number and types of Symptom Subgroups differ based on cancer diagnosis. However, no research has compared Symptom Subgroups in heterogeneous populations based on cancer diagnosis. The purpose of this study was to: (1) identify the clustering of four highly prevalent symptoms (pain, fatigue, sleep disturbance, and depression), and (2) compare symptom clusters across the seven populations of cancer survivors (prostate, non-small cell lung, non-Hodgkin’s lymphoma, breast, uterine, cervical, and colorectal cancer). Methods: This study is a cross-sectional secondary analysis of data obtained from the My-Health study in partnership with four Surveillance, Epidemiology, and End Results (SEER) cancer registries located in California (two), Louisiana, and New Jersey. The sample included 4,762 cancer survivors 6-13 months following diagnosis of one of the seven cancer types mentioned. Latent class profile analysis was used. Results: Subjects were primarily young (59% age 21-64 years), Caucasian (41%), married/cohabitating (58%) and unemployed (55%). The number of symptom subgroups varied across these seven cancer populations: (1) four-class solution in prostate, lung, non-Hodgkin’s lymphoma, and breast cancer survivors; (2) three-class solution in uterine and cervical cancer survivors; and (3) two-class solution in colorectal cancer survivors. Conclusion: Identifying symptom subgroups by cancer diagnosis has the potential to develop innovative and effective targeted interventions in cancer survivors. Further research is needed to establish extensive knowledge in symptom clustering between treatment regimens, and short-term and long-term cancer survivors.

show abstract

Section: Discussioncontrasting

confidence: 99%

Comparing Symptom Clusters in Cancer Survivors by Cancer Diagnosis: A Latent Class Profile Analysis

Lee,

Han,

Saligan

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Subjective assessments measuring perceived cognitive impairment for CRCI are frequently used as well. Three studies applied subjective assessments including Perceived Cognitive Impairments (CogPCI) subscale [ 33 ] and EORTC QLQ-C30 cognitive function subscale [ 31 , 35 ]. Among neuro-psychological tests, a comprehensive list of cognitive domains was identified including verbal learning and memory, verbal fluency, expressive and receptive language, visuospatial memory, working memory, attention, executive function, processing speed and visual attention, mental flexibility, verbal and visual reasoning, and motor coordination.…”

Section: Resultsmentioning

confidence: 99%

“…(Memory) 10, 11 Abbreviations. COWA Controlled Oral Word Association, HVLT-R Hopkins Verbal Learning Test-Revised, CANTAB Cambridge Neuropsychological Test Automated Battery, WAIS-R Wechsler Adult Intelligence Scale-Revised, TMT Trail Making Test, MMSE Mini-Mental State Examination, CogPCI Perceived Cognitive Impairments subscale, SPMSQ Short Portable Mental State Questionnaire, FACT-Cog Functional Assessment of Cancer Therapy, EORTC QLQ-C30 European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire References in this table: 1[ 37 ]; 2[ 36 ]; 3[ 27 ]; 4[ 28 ]; 5[ 33 ]; 6[ 29 ]; 7[ 30 ]; 8[ 34 ]; 9[ 38 ]; 10[ 35 ]; 11[ 31 ] …”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence and assessment tools of cancer-related cognitive impairment in lung cancer survivors: a systematic review and proportional meta-analysis

Ho,

So,

Fan

et al. 2024

Support Care Cancer

View full text Add to dashboard Cite

Purpose Cancer-related cognitive impairment (CRCI) is a significant risk factor influencing the quality of life in lung cancer survivors. No absolute assessment tool has been confirmed to assess CRCI in lung cancer survivors. This review was undertaken to pool the overall prevalence of CRCI and to summarize the assessment tools in assessing CRCI among lung cancer survivors. Methods PubMed, Cochrane Library, Embase, CINAHL, and CNKI were searched to retrieve articles reported CRCI prevalence. Summary prevalence estimates were pooled using a random effects model, along with corresponding 95% prediction intervals (PIs). The Freeman-Tukey double arcsine transformation of proportions was incorporated in the analysis. Additionally, subgroup analysis, meta-regression, and leave-one-out analysis were performed. Results A total of 12 studies, involving 1934 survivors, were included in the review. All of these studies were found to have a low risk of bias in terms of their methodological quality. Four studies (33.3%) utilized the International Cognition and Cancer Task Force (ICCTF) criteria to identify CRCI through neuropsychological tests. The pooled prevalence rate of CRCI was found to be 26% (95% PI, 16–37%), I2 = 95.97%. The region in which the studies were conducted was identified as a significant factor contributing to this heterogeneity (p = 0.013). No indication of small-study effects was found (Egger’s test: p = 0.9191). Conclusion This review provides an overview of CRCI prevalence and assessment tools in lung cancer survivors. The findings can serve as epidemiological evidence to enhance clinicians’ and researchers’ understanding of early detection and assessment.

show abstract

“…Although the estimated heritability of these mutations is 18% (Rifkin et al, 2023), most lung cancer cases are triggered by smoking (Rustagi et al, 2023). Individuals affected by this disease present a cluster of symptoms encompassed by chest pain, fatigue, sleep deprivation, cough, dyspnea, hemoptysis, and weight loss (Ruano-Raviña et al, 2020;Luo et al, 2023). Thereupon, given the escalated incidence and severity of this type of cancer, miRNAloaded NPs have received significant attention in the last years due to their clinical significance in the modulation of oncogenic protein expression.…”

Section: Lung Cancermentioning

confidence: 99%

Applications of nanotechnologies for miRNA-based cancer therapeutics: current advances and future perspectives

Bravo-Vázquez,

Méndez-García,

Rodríguez

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are short (18–25 nt), non-coding, widely conserved RNA molecules responsible for regulating gene expression via sequence-specific post-transcriptional mechanisms. Since the human miRNA transcriptome regulates the expression of a number of tumor suppressors and oncogenes, its dysregulation is associated with the clinical onset of different types of cancer. Despite the fact that numerous therapeutic approaches have been designed in recent years to treat cancer, the complexity of the disease manifested by each patient has prevented the development of a highly effective disease management strategy. However, over the past decade, artificial miRNAs (i.e., anti-miRNAs and miRNA mimics) have shown promising results against various cancer types; nevertheless, their targeted delivery could be challenging. Notably, numerous reports have shown that nanotechnology-based delivery of miRNAs can greatly contribute to hindering cancer initiation and development processes, representing an innovative disease-modifying strategy against cancer. Hence, in this review, we evaluate recently developed nanotechnology-based miRNA drug delivery systems for cancer therapeutics and discuss the potential challenges and future directions, such as the promising use of plant-made nanoparticles, phytochemical-mediated modulation of miRNAs, and nanozymes.

show abstract

The high burden of symptoms associated with cognitive impairment in lung cancer patients: A latent class analysis

Cited by 13 publications

References 48 publications

Comparing Symptom Clusters in Cancer Survivors by Cancer Diagnosis: A Latent Class Profile Analysis

Comparing Symptom Clusters in Cancer Survivors by Cancer Diagnosis: A Latent Class Profile Analysis

Prevalence and assessment tools of cancer-related cognitive impairment in lung cancer survivors: a systematic review and proportional meta-analysis

Applications of nanotechnologies for miRNA-based cancer therapeutics: current advances and future perspectives

Contact Info

Product

Resources

About